NASDAQ:SRRK

Scholar Rock - SRRK Stock Forecast, Price & News

$7.36

-0.65 (-8.12%)

(As of 03/28/2023 12:00 AM ET)

Add

Compare

Today's Range: $7.29
▼
$8.03
50-Day Range: $7.36
▼
$12.72
52-Week Range: $4.32
▼
$15.32

Volume: 255,923 shs
Average Volume: 256,429 shs
Market Capitalization: $382.39 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.67

Institutional Ownership

Scholar Rock MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 249.0% Upside
$25.67 Price Target
Short Interest: Bearish
6.48% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.78
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$455,061 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.38) to ($2.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

411th out of 1,002 stocks

Biological Products, Except Diagnostic Industry

72nd out of 166 stocks

3.5

Analyst's Opinion

Consensus Rating
Scholar Rock has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.67, Scholar Rock has a forecasted upside of 249.0% from its current price of $7.36.
Amount of Analyst Coverage
Scholar Rock has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
6.48% of the outstanding shares of Scholar Rock have been sold short.
Short Interest Ratio / Days to Cover
Scholar Rock has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Scholar Rock has recently increased by 11.22%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Scholar Rock does not currently pay a dividend.
Dividend Growth
Scholar Rock does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Scholar Rock has received a 74.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Scholar Rock is -0.78.

3.3

News and Social Media Coverage

News Sentiment
Scholar Rock has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Scholar Rock this week, compared to 1 article on an average week.
Search Interest
10 people have searched for SRRK on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Scholar Rock insiders have bought 4,287.82% more of their company's stock than they have sold. Specifically, they have bought $455,061.00 in company stock and sold $10,371.00 in company stock.
Percentage Held by Insiders
Only 2.05% of the stock of Scholar Rock is held by insiders.
Percentage Held by Institutions
91.63% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Scholar Rock are expected to decrease in the coming year, from ($2.38) to ($2.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Scholar Rock is -3.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Scholar Rock is -3.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Scholar Rock has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Stock News Headlines

March 7, 2023 | msn.com

Scholar Rock GAAP EPS of -$2.26 beats by $0.02, revenue of $33.19M in-line

March 7, 2023 | finance.yahoo.com

Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress

March 28, 2023 | Weiss Ratings (Ad)

Urgent Warning

This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …

March 1, 2023 | finance.yahoo.com

Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

February 27, 2023 | finance.yahoo.com

Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference

February 17, 2023 | finance.yahoo.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 11, 2023 | finance.yahoo.com

Shareholders in Scholar Rock Holding (NASDAQ:SRRK) have lost 43%, as stock drops 13% this past week

February 6, 2023 | finance.yahoo.com

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

March 28, 2023 | Weiss Ratings (Ad)

Urgent Warning

January 11, 2023 | seekingalpha.com

Scholar Rock Holding (SRRK) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow

January 11, 2023 | nypost.com

Calling all NY high school students: Enter the New York Post Scholars Contest

January 9, 2023 | finance.yahoo.com

Scholar Rock Provides Corporate Update and Highlights Priorities for 2023

January 3, 2023 | finance.yahoo.com

Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference

November 16, 2022 | finance.yahoo.com

Scholar Rock Holding Third Quarter 2022 Earnings: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

November 14, 2022 | finance.yahoo.com

Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress

November 10, 2022 | finance.yahoo.com

Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy

November 9, 2022 | finance.yahoo.com

Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer

October 30, 2022 | msn.com

Over $1 Million Bet On Scholar Rock Holding? 3 Stocks Insiders Are Buying

October 28, 2022 | benzinga.com

1.05M Reasons To Be Bullish On Scholar Rock Holding Stock

October 22, 2022 | finance.yahoo.com

New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

October 20, 2022 | seekingalpha.com

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

October 18, 2022 | nasdaq.com

Scholar Rock Holding (NASDAQ:SRRK) shareholders have endured a 73% loss from investing in the stock a year ago

October 6, 2022 | finance.yahoo.com

Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting

October 4, 2022 | finance.yahoo.com

Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy

October 3, 2022 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Scholar Rock Holding (SRRK)

September 23, 2022 | finance.yahoo.com

Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 21, 2022 | seekingalpha.com

Jay Backstrom is the new CEO at Scholar Rock

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Company Calendar

Last Earnings: 3/07/2023
Today: 3/28/2023
Next Earnings (Estimated): 5/15/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SRRK
CUSIP: N/A
CIK: 1727196
Web: www.scholarrock.com
Phone: (857) 259-3860
Fax: 866-493-4935
Employees: 145
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $25.67
High Stock Price Forecast: $33.00
Low Stock Price Forecast: $19.00
Forecasted Upside/Downside: +222.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-134,500,000.00
Net Margins: N/A
Pretax Margin: -405.21%
Return on Equity: -51.03%
Return on Assets: -37.40%

Debt

Debt-to-Equity Ratio: 0.19
Current Ratio: 9.01
Quick Ratio: 9.01

Sales & Book Value

Annual Sales: $33.19 million
Price / Sales: 12.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.04 per share
Price / Book: 1.58

Miscellaneous

Outstanding Shares: 51,990,000
Free Float: 50,919,000
Market Cap: $414.36 million
Optionable: Not Optionable
Beta: 0.78

Key Executives

Jay T. Backstrom
President, Chief Executive Officer & Director

Edward H. Myles
Chief Financial Officer & Head-Business Operations

Mohammed Qatanani
Senior Vice President & Head-Research

Jing L. Marantz
Chief Medical Officer

Erin Moore
Senior Vice President-Finance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SRRK Stock - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings or view top-rated stocks.
What is Scholar Rock's stock price forecast for 2023?: 5 brokers have issued 1-year price targets for Scholar Rock's stock. Their SRRK share price forecasts range from $19.00 to $33.00. On average, they anticipate the company's stock price to reach $25.67 in the next year. This suggests a possible upside of 222.0% from the stock's current price.
View analysts price targets for SRRK or view top-rated stocks among Wall Street analysts.
How have SRRK shares performed in 2023?: Scholar Rock's stock was trading at $9.05 at the start of the year. Since then, SRRK shares have decreased by 11.9% and is now trading at $7.97.
View the best growth stocks for 2023 here.
When is Scholar Rock's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our SRRK earnings forecast.
How were Scholar Rock's earnings last quarter?: Scholar Rock Holding Co. (NASDAQ:SRRK) posted its quarterly earnings results on Tuesday, March, 7th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.11. During the same quarter in the previous year, the company posted ($0.97) earnings per share.
What ETFs hold Scholar Rock's stock?: ETFs with the largest weight of Scholar Rock (NASDAQ:SRRK) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB) and
What other stocks do shareholders of Scholar Rock own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?: (SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
What is Scholar Rock's stock symbol?: Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."
Who are Scholar Rock's major shareholders?: Scholar Rock's stock is owned by a number of institutional and retail investors. Top institutional investors include Artal Group S.A. (17.38%), Price T Rowe Associates Inc. MD (13.62%), T. Rowe Price Investment Management Inc. (4.77%), Bank of America Corp DE (2.03%), Geode Capital Management LLC (0.70%) and Morgan Stanley (0.59%). Insiders that own company stock include Amir Nashat, Edward H Myles, Gregory John Carven, Jeffrey S Flier, Michael Gilman and Public Equities LP Invus.
View institutional ownership trends.
How do I buy shares of Scholar Rock?: Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Scholar Rock's stock price today?: One share of SRRK stock can currently be purchased for approximately $7.97.
How much money does Scholar Rock make?: Scholar Rock (NASDAQ:SRRK) has a market capitalization of $414.36 million and generates $33.19 million in revenue each year. The company earns $-134,500,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.
How many employees does Scholar Rock have?: The company employs 145 workers across the globe.
How can I contact Scholar Rock?: Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935.

This page (NASDAQ:SRRK) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Scholar Rock - SRRK Stock Forecast, Price & News

Scholar Rock MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Scholar Rock (NASDAQ:SRRK) Stock

SRRK Stock News Headlines

SRRK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SRRK Stock - Frequently Asked Questions

Overall MarketRank^™